WELCOME TO MICROBIOME CONNECT: ASIA
With APAC set to experience transformative growth, the need to build meaningful connections with microbiome biotechs, pharma voices, government officials, and investment bodies has never been stronger.
For developers of microbiome-based therapeutics, Microbiome Connect: Asia is a unique opportunity to advance your company along its commercialisation journey.
Following our flagship US and EU events, this forum is dedicated to accelerating pipeline development in APAC by showcasing updates from leading biotechs, addressing regional regulatory issues, and promoting collaboration between industry, academia, and service providers.
Join us in the hub of Asian microbiome research to adopt effective manufacturing strategies to achieve commercial scale, build collaborative relationships with regulatory bodies, and address current challenges associated with GMP production in Korea and beyond.
MICROBIOME CONNECT NETWORK
Past attendees, reflective of 2022.
EVENT SCHEDULE
Microbiome Connect: Asia will return in 2024.
In the meantime, download your copy of the Microbiome Connect: Europe agenda - discover the full line-up of industry leaders joining us in Amsterdam to share their insights.
To find out more about the Microbiome Connect: USA, check out the website here to discover what you can expect in November 2023.
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
DOWNLOAD THE EUROPE AGENDA
2023 PRE-CLINICAL PROGRAM SHOWCASE COMPETITION JUDGES
Sou Miyake
Jun Terauchi
SeungHwan Lee
2023 SPEAKER FACULTY
Jisoo Pae, MD, Psychiatrist, MBA
Clay (Young Suk) Kim, M.A.
Sin-Hyeog Im, Ph.D.
GwangPyo Ko, Ph.D.
Jun Terauchi
Jongmin Paek
Sang Sun Yoon, Ph.D.
Mirjana Rapaic
Byoung-Chan Kim
Dr Byoung-Chan Kim received his B.S, M.S, and Ph.D. from Yonsei University (Department of Biotechnology) and is currently serving as Chief Executive Officer of HealthBiome Inc. His research interests include: isolation, taxonomic classification & fermentation of strict anaerobic bacteria. Dr Kim’s past roles include Professor of Microbiology at UMass, USA, and Senior/Principal Investigator at the Korea Research Institute of Bioscience & Biotechnology (KRIBB).
Aaron Cowley, Ph.D., MBA
Samantha Coulson, Ph.D.
Taku Nakahara, Ph.D., MBA
Kumar Sankaran
Dr. Song, Managing Director of LISCure, worked as a postdoc and instructor at Tulane University, School of Medicine, researching liver cancer and nonalcoholic steatohepatitis. He led the research and development of drugs for NASH and autoimmune diseases in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He plays an important role in LISCure’s lab as well as global partnerships with Mayo Clinic and Scripps Labs.
Sarah Haylock-Jacobs
Sarah is a PhD scientist with over 5 years experience designing and coordinating clinical trials in North America and Australia.
She has experience with FDA and TGA governed clinical trials and co-ordinating hospital sites on large multicentre studies.
Kyoungsub Song Ph.D.
Kyoungsub Song has more than 15 years experience in the field of liver disease including NASH, cirrhosis, and cancers. He worked as a postdoc and instructor at Tulane University, School of Medicine. He joined LISCure Bioscience in 2020 and now serves as CTO. He led the research and development drugs for NASH in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He was actively involved in LISCure’s global partnerships with Mayo Clinic and Scripps research.
Renato Lemgruber
Bachelor's Degree in Biological Sciences (Federal University of Parana, Brazil, 2009).
Master of Science in Genetics, Conservation and Evolutionary Biology (National Institute of Amazonian Research, Brazil, 2012).
PhD in Biotechnology (Systems and Synthetic Biology) (Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia, 2019).
Member of The Higher Education Academy (HEA) as an Associate Fellow (Since March 2019)
Henri de Vlam
Antonio Fernandez Medarde
Mo Langhi
Taous Saraoui
Max Rossetto
OUR PROUD 2023 SPONSORS
Headline Partner
Bacthera
Website: https://www.bacthera.com/
Bacthera is a Danish/Swiss-based one-stop CDMO in the field of LBP’s, with the overall goal to enable the entire industry to further flourish by introducing industry changing innovations.
From small start-up’s to globally operating pharmaceutical companies, we support our clients developing analytical and manufacturing processes of their strains. With our long experience in handling bacteria in DS and DP production, we can offer tailor-made development and large-scale commercial solutions. Within our facilities, we can handle:
- Strictly and facultative anaerobes
- BSL1/2 categorized strains
- GMO’s
Our customers benefit from background technologies and GMP manufacturing know-how that originate from our mother companies Chr. Hansen & Lonza. In addition, Bacthera’s process expertise, enabling innovations and our world-class analytical services will contribute to our customer’s successful development of their LBP.
Platinum Partner
Biose Industrie
Website: https://www.biose.com/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
CosmosID
Website: www.cosmosid.com
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for research and development.
CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision. Results can be accessed via CosmosID-HUB, a user-friendly and interactive software for comparative analysis of microbiome data, complete with dynamic charts, visualizations, and statistics.
Gold Partners
Silver Partner
Sacco Systems
Website: https://www.saccosystem.com/home/en/
Please visit our website for more information.Event Partner
CKD Bio
Website: https://www.ckdbio.com/en/home
CKD Bio Corporation is devoted to serving the better life through better medicines, with over 70-years experience in the pharmaceutical industry. CKD Bio manufactures the highest quality intermediates and APIs through fully integrated manufacturing process from fermentation to chemical synthesis. CKD Bio is specialized in Contract Manufacturing and Contract Research in the field of fermentation
Quay Pharma
Website: https://www.quaypharma.com
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Start Bioservices
Website: https://startbioservices.com/
Start Bioservices, an innovative CDMO, focuses on advanced therapies which help pharmaceutical companies complete process development and GMP manufacturing. Our innovative services market and support client programs around the world; saving valuable time and money.
Start Bioservices utilizes state-of-the-art platform technology to efficiently and economically create customized plasmid products for clients.
Starting with the target gene DNA provided by clients, we offer GMP plasmid strain bank production services, high-expression plasmid production services and off-the-shelf standardized product services to meet client needs.
Media & press partners
BioSpectrum Asia
Website: https://www.biospectrumasia.com/
Please visit our website for more information.Korea Biomedical Review
Website: https://www.koreabiomed.com/
Please visit our website for more information.Pharma Focus Asia
Website: https://www.pharmafocusasia.com/
Please visit our website for more information.GET INVOLVED
SPONSORSHIP
Let us create a bespoke package based on your specific objectives, and showcase your brand to the microbiome community.
Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
Contact [email protected]
MEDIA & PRESS
Connecting the microbiome community is essential for progress in the field.
We'd love to hear from you and how we can support one another to connect leaders in the industry and share important insights.
Contact [email protected] if you have any questions. For more information on marketing solutions and digital opportunities, download the Media Kit below.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
